DK1237886T3 - Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor - Google Patents
Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptorInfo
- Publication number
- DK1237886T3 DK1237886T3 DK00983240T DK00983240T DK1237886T3 DK 1237886 T3 DK1237886 T3 DK 1237886T3 DK 00983240 T DK00983240 T DK 00983240T DK 00983240 T DK00983240 T DK 00983240T DK 1237886 T3 DK1237886 T3 DK 1237886T3
- Authority
- DK
- Denmark
- Prior art keywords
- carboxylic acid
- acid compound
- nmda receptor
- quinoline carboxylic
- compound active
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title 1
- -1 quinoline carboxylic acid compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9929037.1A GB9929037D0 (en) | 1999-12-08 | 1999-12-08 | Heterocyclic derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1237886T3 true DK1237886T3 (da) | 2006-08-14 |
Family
ID=10865952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00983240T DK1237886T3 (da) | 1999-12-08 | 2000-12-07 | Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6713491B2 (cs) |
| EP (1) | EP1237886B1 (cs) |
| JP (1) | JP4311901B2 (cs) |
| KR (1) | KR100788579B1 (cs) |
| CN (1) | CN1325488C (cs) |
| AR (1) | AR030923A1 (cs) |
| AT (1) | ATE323691T1 (cs) |
| AU (1) | AU769232B2 (cs) |
| BR (1) | BR0016235A (cs) |
| CA (1) | CA2393303C (cs) |
| CO (1) | CO5251474A1 (cs) |
| CY (1) | CY1106105T1 (cs) |
| CZ (1) | CZ301052B6 (cs) |
| DE (1) | DE60027461T2 (cs) |
| DK (1) | DK1237886T3 (cs) |
| ES (1) | ES2257343T3 (cs) |
| GB (1) | GB9929037D0 (cs) |
| HK (1) | HK1047436B (cs) |
| HU (1) | HUP0203650A3 (cs) |
| IL (2) | IL150010A0 (cs) |
| MX (1) | MXPA02005802A (cs) |
| MY (1) | MY129892A (cs) |
| NO (1) | NO323263B1 (cs) |
| PL (1) | PL356713A1 (cs) |
| PT (1) | PT1237886E (cs) |
| TN (1) | TNSN00240A1 (cs) |
| TR (1) | TR200201503T2 (cs) |
| TW (1) | TW524804B (cs) |
| WO (1) | WO2001042238A1 (cs) |
| ZA (1) | ZA200204492B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585988B2 (en) * | 2003-04-25 | 2009-09-08 | Nippon Chemiphar Co., Ltd. | Salt of (2S, 3S) -3- [[(1S) -1- isobutoxymethyl-3-methylbutyl] carbamoly] oxirane-2-carboxylic acid |
| GB0327912D0 (en) * | 2003-12-02 | 2004-01-07 | Glaxo Group Ltd | Medicament |
| US7576216B2 (en) | 2004-07-30 | 2009-08-18 | Abbott Laboratories | Preparation of pyridonecarboxylic acid antibacterials |
| EP3957632A1 (en) * | 2004-10-08 | 2022-02-23 | AbbVie Inc. | Meglumine salt and crystalline forms thereof of a drug (delafloxacin) |
| SI1868581T1 (sl) * | 2005-04-11 | 2012-06-29 | Abbott Lab | Farmacevtski sestavki z izboljšanim profilom topnosti za slabo topna zdravila |
| EP2776023B1 (en) | 2011-10-25 | 2016-03-09 | Janssen Pharmaceutica, N.V. | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| US5529999A (en) | 1994-03-04 | 1996-06-25 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| US6413959B1 (en) * | 1995-04-14 | 2002-07-02 | Boehringer Ingelheim Kg | Method of treating depression with arylglycinamide derivatives |
| DE69622731T2 (de) | 1995-09-29 | 2003-02-20 | Glaxosmithkline S.P.A., Verona | Tetrahydrochinoline als nmda antagonisten |
| GB9617305D0 (en) | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
| MY125037A (en) * | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
-
1999
- 1999-12-08 GB GBGB9929037.1A patent/GB9929037D0/en not_active Ceased
-
2000
- 2000-07-12 US US10/148,434 patent/US6713491B2/en not_active Expired - Fee Related
- 2000-12-06 MY MYPI20005714A patent/MY129892A/en unknown
- 2000-12-07 HK HK02109085.5A patent/HK1047436B/en not_active IP Right Cessation
- 2000-12-07 HU HU0203650A patent/HUP0203650A3/hu unknown
- 2000-12-07 EP EP00983240A patent/EP1237886B1/en not_active Expired - Lifetime
- 2000-12-07 BR BR0016235-3A patent/BR0016235A/pt not_active Application Discontinuation
- 2000-12-07 DE DE60027461T patent/DE60027461T2/de not_active Expired - Lifetime
- 2000-12-07 ES ES00983240T patent/ES2257343T3/es not_active Expired - Lifetime
- 2000-12-07 JP JP2001543537A patent/JP4311901B2/ja not_active Expired - Fee Related
- 2000-12-07 TR TR2002/01503T patent/TR200201503T2/xx unknown
- 2000-12-07 TW TW089126096A patent/TW524804B/zh not_active IP Right Cessation
- 2000-12-07 AU AU20060/01A patent/AU769232B2/en not_active Ceased
- 2000-12-07 WO PCT/EP2000/012335 patent/WO2001042238A1/en not_active Ceased
- 2000-12-07 PT PT00983240T patent/PT1237886E/pt unknown
- 2000-12-07 CN CNB00816875XA patent/CN1325488C/zh not_active Expired - Fee Related
- 2000-12-07 DK DK00983240T patent/DK1237886T3/da active
- 2000-12-07 CZ CZ20021981A patent/CZ301052B6/cs not_active IP Right Cessation
- 2000-12-07 MX MXPA02005802A patent/MXPA02005802A/es active IP Right Grant
- 2000-12-07 AT AT00983240T patent/ATE323691T1/de active
- 2000-12-07 KR KR1020027007260A patent/KR100788579B1/ko not_active Expired - Fee Related
- 2000-12-07 AR ARP000106511A patent/AR030923A1/es unknown
- 2000-12-07 CA CA002393303A patent/CA2393303C/en not_active Expired - Fee Related
- 2000-12-07 CO CO00093651A patent/CO5251474A1/es not_active Application Discontinuation
- 2000-12-07 IL IL15001000A patent/IL150010A0/xx unknown
- 2000-12-07 PL PL00356713A patent/PL356713A1/xx not_active Application Discontinuation
- 2000-12-08 TN TNTNSN00240A patent/TNSN00240A1/en unknown
-
2002
- 2002-06-03 IL IL150010A patent/IL150010A/en not_active IP Right Cessation
- 2002-06-05 ZA ZA200204492A patent/ZA200204492B/xx unknown
- 2002-06-06 NO NO20022682A patent/NO323263B1/no not_active IP Right Cessation
-
2004
- 2004-02-10 US US10/775,709 patent/US6943176B2/en not_active Expired - Fee Related
-
2006
- 2006-06-26 CY CY20061100855T patent/CY1106105T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI20002767L (fi) | Jodoniumsuolat latentteina happodonoreina | |
| NO20024387L (no) | Karboksylsyrederivater som IP-antagonister | |
| DK0981527T3 (da) | Salt af et naphthyridincarboxylsyrederivat | |
| DK1163207T3 (da) | Forbedret fremgangsmåde til fremstillingen af ikke-hygroskopiske salte af L(-)-carnitin | |
| DK1189916T3 (da) | N-pyrazol A 2A-receptoragonister | |
| BR0005305B1 (pt) | absorvente higiÊnico composto. | |
| BR0005300B1 (pt) | absorvente higiÊnico composto. | |
| NO20011349D0 (no) | 4-Aminosubstituerte 2-substituerte 1,2,3,4- tetrahydrokinoliner som CETP inhibitorer | |
| DK0888317T3 (da) | Substituerede 4-hydroxy-phenylalkansyrederivater med agonistaktivitet over for PPAR-gamma | |
| EE9900550A (et) | S-omeprasooli uus vorm | |
| CY2009011I1 (el) | Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης | |
| NO20016319D0 (no) | VLA-4 inhibitor-forbindelser | |
| ATE305470T1 (de) | Naphthyridinverbindungen | |
| FI20000869A0 (fi) | Menetelmä kiinnirullaimen toimintavarmuuden parantamiseksi | |
| DE60039136D1 (de) | Plattenaufzeichnungssystem | |
| IS2212B (is) | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide | |
| DK1328499T3 (da) | Fremgangsmåde til fremstilling af carboxylsyresalte | |
| NO331228B1 (no) | Anvendelse av en sammensetning som omfatter et ketotifensalt | |
| HRPK20040372B3 (en) | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist | |
| DK1237886T3 (da) | Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor | |
| DK1228073T3 (da) | Imidazolforbindelser som phosphodiesterase VII-inhibitorer | |
| IS6400A (is) | Kristallað form (S)-2-etoxý-3-[4-(2-{4-metansúlfonýlfenýl}etoxý)fenýl]própanónsýra | |
| NO20020774D0 (no) | Farmasöytisk middel omfattende et benzamid-derivat som aktiv forbindelse | |
| DK1233755T3 (da) | Hydrolyseret cellulosegranuleringer af salte af lægemidler | |
| DK1114050T3 (da) | Fremgangsmåde til fremstilling af et naphthyridincarboxylsyrederivat (methansulfonat-sesquihydrat) |